Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 06 May 2026 | Laszlo Kristoffy Cabinet member | Health package | SRC |
| 28 Apr 2026 | Jana Dabbelt Cabinet member | EUCOPE - Strasbourg | — |
| 28 Apr 2026 | Jana Dabbelt Cabinet member | EUCOPE - Strasbourg | SRC |
| 31 Mar 2026 | Paulina Dejmek Hack Cabinet member | Sustainable technologies | SRC |
| 31 Mar 2026 | Paulina Dejmek Hack Cabinet member | Sustainable technologies | — |
| 12 Mar 2026 | Jessika Roswall Commissioner | Discussion on innovation in Europe. And exchange of views on the topic PFAS. | SRC |
| 12 Mar 2026 | Jessika Roswall Commissioner | Discussion on innovation in Europe. And exchange of views on the topic PFAS. | — |
| 05 Mar 2026 | Patricia Reilly Cabinet member | Exchange on EU health and industrial policies | SRC |
| 05 Mar 2026 | Patricia Reilly Cabinet member | Exchange on EU health and industrial policies | — |
| 03 Feb 2026 | Carmen Laplaza Santos Head of Unit | Exchange of views on the competitiveness of the European pharmaceutical sector. | — |
| 03 Feb 2026 | Carmen Laplaza Santos Head of Unit | Exchange of views on the competitiveness of the European pharmaceutical sector. | SRC |
| 21 Jan 2026 | Olivér Várhelyi Commissioner | Health Package | — |
| 21 Jan 2026 | Laszlo Kristoffy Cabinet member | Health Package | SRC |
| 21 Jan 2026 | Olivér Várhelyi Commissioner | Health Package | SRC |
| 21 Jan 2026 | Laszlo Kristoffy Cabinet member | Health Package | — |
| 03 Dec 2025 | Ulla Schwager Head of Unit | Exchange of views on developments in the pharmaceutical industry and aspects of competition law and policy enforcement in this industry sector | SRC |
| 03 Dec 2025 | Ulla Schwager Head of Unit | Exchange of views on developments in the pharmaceutical industry and aspects of competition law and policy enforcement in this industry sector | — |
| 18 Nov 2025 | Saila Rinne Head of Unit | AI in health. | — |
| 18 Nov 2025 | Saila Rinne Head of Unit | AI in health. | SRC |
| 07 Oct 2025 | Chiara Galiffa Cabinet member | US and EU trade relations in the context of the pharmaceutical sector | — |
| 07 Oct 2025 | Chiara Galiffa Cabinet member | US and EU trade relations in the context of the pharmaceutical sector | SRC |
| 04 Sept 2025 | Rainer Becker Director | Exchange of views on multinational clinical trials in the context of the upcoming Biotech Act | — |
| 04 Sept 2025 | Rainer Becker Director | Exchange of views on multinational clinical trials in the context of the upcoming Biotech Act | SRC |
| 14 Jul 2025 | Patricia Reilly Cabinet member | Competitiveness of the biopharmaceutical sector | SRC |
| 14 Jul 2025 | Patricia Reilly Cabinet member | Competitiveness of the biopharmaceutical sector | — |
Mission & Goals
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
EU Legislative Interests
AstraZeneca monitors and follows policy of relevance for the biopharmaceutical sector. It interacts with the EU institutions and engages in issues relating to healthcare, pharmaceuticals, patient safety, research and innovation, competitiveness and internal market, intellectual property, trade, simplification, sustainability, and public health including: - Reform of the General Pharmaceutical Legislation (Regulation 726/2004 and Directive 2001/83/EC) - European Biotech Act - Critical Medicines Act - Environmental Omnibus - Sustainable healthcare financing
Communication Activities
Engaging with EU policy makers and stakeholders, directly or withe trade associations. AstraZeneca monitors and follows policy of relevance for the biopharmaceutical sector. It interacts with the EU institutions and engages in issues relating to healthcare, pharmaceuticals, patient safety, research and innovation, trade, competitiveness, and internal market. AstraZeneca partnered with stakeholders over several initiatives over the past registrable period: - Contributed to the Partnership for Health System Sustainability and Resilience's EU Report on Investing in Health for a Competitive, Secure, and Resilient Europe: A Strategic Call to Action: https://reports.weforum.org/docs/WEF_PHSSR_European_Union_Investing_in_Health_2025.pdf - Sponsored and participated in the Politico EU Health Care Summit - Sponsored and participated in the Economist Impact's World Cancer Series: Europe even
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
AstraZeneca is a Member of: - European Federation of Pharmaceutical Industries and Associations (EFPIA) - www.efpia.eu; (including their national trade association members) - International Pharmaceutical Aerosol Consortium (IPAC) - www.ipacinhaler.org - European Roundtable For Industry (ERT) - www.ert.eu - Vaccines Europe AstraZeneca also sponsors / contributes to patient advocacy or relevant expert groups, the following of which engage with EU institutions: - European Federation of Allergies and Airways (EFA) - https://www.efanet.org - European Cancer Organisation - European Patient Forum - European Patient Safety Foundation - Heart Failure Policy Network - Lung Cancer Policy Network - EUPATI - European Patients Academy on Therapeutic Innovation - European Kidney Patient Federation - European Kidney Health Alliance - World Bladder Cancer Patients Organisation - Advance Breast Cancer Global Alliance - European Policy Centre
Connected Legislation